CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
细胞疗法自诞生以来，经过快速发展，已经彻底改变了血液系统恶性肿瘤的治疗格局。嵌合抗原受体（CAR）-T细胞疗法是应用最广泛的细胞疗法。自2017年美国食品药品监督管理局批准两款CD19-CAR-T 产品用于临床治疗复发/难治性急性淋巴细胞白血病和弥漫性大B细胞淋巴瘤以来，随后又有五款CAR-T 细胞产品获批用于治疗多发性骨髓瘤或B细胞恶性肿瘤。此外，针对其他血液系统恶性肿瘤的CAR-T 细胞疗法临床试验正在进行中。中国和美国在临床试验的发展中都做出了重要贡献。然而，CAR-T 细胞疗法存在诸多局限性，如高复发率、不良副作用和可及性受限。临床试验中正在采用多种方法来解决这些问题，其中一些已展现出有前景的突破。本综述总结了CAR-T 细胞试验的进展以及CAR-T 细胞疗法的研究进展。
Cellular therapies have revolutionized the treatment of hematological malignancies since their conception and rapid development. Chimeric antigen receptor (CAR)-T cell therapy is the most widely applied cellular therapy. Since the Food and Drug Administration approved two CD19-CAR-T products for clinical treatment of relapsed/refractory acute lymphoblastic leukemia and diffuse large B cell lymphoma in 2017, five more CAR-T cell products were subsequently approved for treating multiple myeloma or B cell malignancies.
Moreover, clinical trials of CAR-T cell therapy for treating other hematological malignancies are ongoing. Both China and the United States have contributed significantly to the development of clinical trials.
However, CAR-T cell therapy has many limitations such as a high relapse rate, adverse side effects, and restricted availability. Various methods are being implemented in clinical trials to address these issues, some of which have demonstrated promising breakthroughs. This review summarizes developments in CAR-T cell trials and advances in CAR-T cell therapy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
